2.95 -0.07 (-2.32%)
After hours: 6:39PM EDT
|Bid||2.95 x 800|
|Ask||3.02 x 800|
|Day's range||3.00 - 3.13|
|52-week range||2.25 - 4.50|
|PE ratio (TTM)||0.76|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||3.25|
Ophthotech Corporation (OPHT) announced today that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania (Penn) to develop and commercialize a novel adeno-associated virus (AAV) gene therapy product for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), an orphan monogenic disease that is characterized by progressive and severe loss of vision leading to blindness. Preclinical anatomical and functional proof-of-concept studies have demonstrated promising results in a canine disease model. In addition to the exclusive license agreement, Ophthotech and Penn have also entered into a master sponsored research agreement, facilitated by the Penn Center for Innovation (PCI), pursuant to which Ophthotech and Penn plan to conduct preclinical and natural history studies.
On a per-share basis, the New York-based company said it had a loss of 36 cents. The company's shares closed at $2.62. A year ago, they were trading at $2.62. _____ This story was generated by Automated ...
Ophthotech Corporation today announced financial and operating results for the first quarter ended March 31, 2018 and provided a business update.
Ophthotech Corporation (OPHT) today announced the completion of patient enrollment in its Phase 2a clinical trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). Zimura is administered in combination with Lucentis® (ranibizumab), an anti-vascular endothelial growth factor (anti-VEGF) agent, in treatment naïve patients with wet AMD. “We are pleased with the enthusiasm shown by the principal investigators in the recruitment for this clinical trial leading to on time enrollment of patients,” stated Kourous Rezaei, M.D., Chief Medical Officer of Ophthotech.
Ophthotech Corporation (OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. Ophthotech is a science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.
Regeneron (REGN) announces encouraging top-line results from the phase III study evaluating Eylea injection in moderately severe to severe non-proliferative diabetic retinopathy.
Ophthotech Corporation announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13, 2018 at 9:20 a.m.
Ophthotech (OPHT) reports better-than-expected fourth-quarter earnings but misses on sales. The company plans to use novel gene therapy to develop new treatments for ocular diseases.
On a per-share basis, the New York-based company said it had a loss of 26 cents. For the year, the company reported net income of $114.2 million, or $3.17 per share, swinging to a profit in the period. ...
Ophthotech Corporation today announced financial and operating results for the fourth quarter and full year ended December 31, 2017 and provided a business update.
Ophthotech Corporation announced today that the Company has initiated an innovative gene therapy research collaboration focused on applying novel gene therapy technology to discover and develop next-generation therapies for the treatment of ocular diseases.
Ophthotech Corporation today announced that it will report its fourth quarter and full year 2017 financial and operating results on Tuesday, February 27, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m.
Ophthotech Corporation announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura® , complement C5 inhibitor, in patients with autosomal recessive Stargardt disease .
Ophthotech Corporation announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors, effective immediately.
Ophthotech Corporation announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 36th Annual J.P.
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Ophthotech Corporation breached their fiduciary duties to shareholders.
Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.
Ophthotech (OPHT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.
Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.